Literature DB >> 19332087

Dysport: pharmacological properties and factors that influence toxin action.

Andy Pickett1.   

Abstract

The pharmacological properties of Dysport that influence toxin action are reviewed and compared with other botulinum toxin products. In particular, the subject of diffusion is examined and discussed based upon the evidence that currently exists, both from laboratory studies and from clinical data. Diffusion of botulinum toxin products is not related to the size of the toxin complex in the product since the complex dissociates under physiological conditions, releasing the naked neurotoxin to act. The active neurotoxin in Type A products is the same and therefore diffusion is equal when equal doses are administered.

Mesh:

Substances:

Year:  2009        PMID: 19332087     DOI: 10.1016/j.toxicon.2009.03.020

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  15 in total

Review 1.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 2.  Noninvasive Facial Rejuvenation. Part 2: Physician-Directed-Neuromodulators and Fillers.

Authors:  Ryan M Dickey; Matthew R Louis; Joshua A Cox; Kriti Mohan; Edward I Lee; Marjory G Nigro
Journal:  Semin Plast Surg       Date:  2016-08       Impact factor: 2.314

Review 3.  Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment.

Authors:  Alessio Baricich; Alessandro Picelli; Andrea Santamato; Stefano Carda; Alessandro de Sire; Nicola Smania; Carlo Cisari; Marco Invernizzi
Journal:  Clin Drug Investig       Date:  2018-11       Impact factor: 2.859

4.  Consistent biochemical data are essential for comparability of botulinum toxin type A products.

Authors:  Andy Pickett
Journal:  Drugs R D       Date:  2011

5.  Botulinum toxin type A for the management of glabellar rhytids.

Authors:  Anne Marie Tremaine; Jerry L McCullough
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-07

6.  Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data.

Authors:  Andy Pickett
Journal:  Clin Ophthalmol       Date:  2011-09-09

7.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

8.  Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis.

Authors:  Hanan Mohamed El Kahky; Heba Mahmoud Diab; Dalia Gamal Aly; Nehal Magdi Farag
Journal:  Dermatol Res Pract       Date:  2013-10-22

Review 9.  History of Botulinum Toxin Treatment in Movement Disorders.

Authors:  Bahman Jabbari
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-11-28

Review 10.  Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.

Authors:  Francesco Scaglione
Journal:  Toxins (Basel)       Date:  2016-03-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.